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Abstract
Background: Epilepsy is associated with an increased mortality among cirrhosis patients, but the reasons are
unknown. We aimed to determine whether epilepsy is a risk factor for developing hepatic encephalopathy (HE),
which is a strong predictor of mortality.
Methods: We used data from three randomized 1-year trials of satavaptan in cirrhosis patients with ascites. With
Cox regression, we compared the hazard rates of HE grade 1–4 between those cirrhosis patients who did or did
not have epilepsy. We adjusted for confounding by gender, age, cirrhosis etiology, diabetes, history of HE, Model
for Endstage Liver Disease (MELD) score, serum sodium, albumin, lactulose use, rifaximin use, and benzodiazepine/
barbiturate sedation. In a supplementary analysis we examined the association between epilepsy and the hazard
rate of HE grade 2–4.
Results: Of the 1120 cirrhosis patients with ascites, 21 (1.9 %) were diagnosed with epilepsy. These patients had
better liver function at inclusion than the patients without epilepsy (median MELD score 7.9 vs. 11.4), and only one
died during the trials. Nevertheless, seven patients with epilepsy had an HE episode during the follow-up, and the
adjusted hazard ratio of HE grade 1–4 for patients with epilepsy vs. controls was 2.12 (95 % CI 0.99–4.55). The
corresponding hazard ratio of HE grade 2–4 was 3.83 (95 % CI 1.65–8.87).
Conclusions: Our findings suggest that epilepsy is associated with an increased risk of HE in patients with cirrhosis.
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Background
We have previously shown that patients with liver cirrhosis
who have been given a diagnosis of epilepsy have a higher
mortality than other patients with cirrhosis [1]. Unfortu-
nately, we could not determine the reasons for that associ-
ation, and no one else has studied it. However, sporadic
case reports have described that hepatic encephalopathy
(HE) may manifest as status epilepticus [2, 3], and since HE
is a very strong predictor of mortality in cirrhosis patients
[4], we thought that epilepsy might increase the risk of HE
in cirrhosis patients.
Epilepsy has a prevalence of about 3 % among Danish
cirrhosis patients [1], and these patients have a 1-year HE
risk around 15 % [4]. Therefore it is necessary to have a
large cohort of cirrhosis patients to obtain meaningful es-
timates of the association between epilepsy and HE risk.
We had access to the complete original dataset from three
large randomized controlled trials of satavaptan treatment
of ascites in nearly 1200 patients with cirrhosis who were
followed for 1 year, and these data presented a unique op-
portunity to study epilepsy as a risk factor for HE. Sata-
vaptan had no effect on the development of HE [5].
Given this background, the aim of this study was to
examine the effect of epilepsy on HE risk in patients
with cirrhosis. Understanding the risk of HE in patients
with epilepsy may add to our understanding of the
pathogenesis of HE and improve our management of cir-
rhosis patients who have epilepsy.
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Methods
Between July 2006 and December 2008 three multi-
national randomized controlled trials were conducted to
examine whether satavaptan was efficacious in treating
ascites in cirrhosis patients [6]. The three trials included
patients with differing severity of ascites, but were other-
wise similar and included 1,198 patients in total. Patients
with a functioning transjugular intrahepatic portosyste-
mic shunt were excluded from the trials, as were pa-
tients with variceal bleeding or spontaneous bacterial
peritonitis in the 10 days before randomization. Other
reasons for exclusion were: serum creatinine >151 μmol/L,
serum potassium ≥5.0 mmol/L, serum sodium >143 mmol/
L (because satavaptan may increase the serum sodium con-
centration), serum bilirubin >150 μmol/L, INR >3.0, plate-
lets <30,000/mm3, neutrophils <1,000/mm3, hepatocellular
carcinoma exceeding the Milan criteria, use of a potent
modifier of the cytochrome P450 3A pathway, or use of
drugs that increase the risk of Q-T interval prolongation [6].
We excluded 78 patients who were encephalopathic at the
time of randomization (because they were not at risk of de-
veloping HE), leaving 1120 patients for inclusion (Fig. 1). Pa-
tients with a history of HE before randomization were
included in the analyses.
Study design
The planned treatment duration in the trials was
52 weeks, but the second and third trials were stopped
early due to a poor risk-benefit ratio [6]. In all three tri-
als, some patients discontinued the study medication
prematurely, primarily due to adverse events [6]. Irre-
spective of the reason for discontinuation, all patients
were followed for one additional week to assess drug
safety. For the analysis presented here, we stopped follow-
up on the date of the last drug safety assessment, i.e. 1 week
after study completion or premature discontinuation.
Data collection
Data on epilepsy, seizures, and use of antiepileptic drugs
were collected at the time of randomization. The case
report forms described why patients used antiepileptic
drugs, but contained no details about their type of epi-
lepsy or seizures. In our primary analysis, we categorized
patients as having or not having epilepsy on the basis of
epilepsy diagnoses recorded at randomization. Due to
concern that epilepsy diagnoses were incorrect, we con-
ducted a secondary analysis in which our neurologist co-
authors (JC and KW) used all the available information
to re-categorize patients as follows: patients with definite
epilepsy (all 8 patients with a recorded diagnosis of epi-
lepsy who were using antiepileptic drugs), patients with
unspecified seizures (12 of 13 patients with a recorded
diagnosis of epilepsy who were not using antiepileptic
drugs; 1 of 13 patients was re-categorized as a control),
patients who used antiepileptic drugs for neuropathy or
other indications, and controls. We defined antiepileptic
drugs by the ATC-code N03A*. Of the 12 patients with
unspecified seizures, three had a history of HE before in-
clusion. We did not have the data to determine whether
these patients’ HE episodes were related to the seizures.
During the follow-up, patients were seen every 4 weeks
in their hepatology departments, and at those visits all
current medications including their indications and dos-
ages were recorded, and blood tests were taken. All HE
episodes and other clinical events were recorded during
the follow-up as part of the safety assessment. Every
Fig. 1 Study flow chart
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four-week visit also included a formal examination for
signs and symptoms of HE by an experienced clinician,
and at the same time the clinician took a history of HE
episodes since the previous visit. There was no psycho-
metric testing for minimal HE. For every HE episode cli-
nicians recorded the severity according to the West
Haven criteria [7], the dates of onset and resolution, and
likely precipitants.
Statistical analysis
For the present analysis, follow-up began at randomization
and continued until the first occurrence of one of the fol-
lowing: onset of an HE episode (grade 1, 2, 3, or 4), death,
or the safety follow-up date following study completion or
premature discontinuation of the study treatment (Fig. 1).
We used the chi-square test (for categorical variables) and
the Mann-Whitney test (for continuous variables) to com-
pute the p-value of the hypothesis that baseline characteris-
tics were identical between cirrhosis patients with or
without epilepsy. We used Cox proportional hazards regres-
sion to examine the association between patient category
and HE hazard rate. We adjusted for confounding by patient
gender, age, cirrhosis etiology (alcohol only [reference],
chronic hepatitis C only, or other etiology), diabetes, history
of HE before randomization, Model for Endstage Liver Dis-
ease (MELD) score, serum sodium, serum albumin, lactu-
lose use, rifaximin use, and benzodiazepine/barbiturate
sedation. This last variable was defined by the ATC codes
N05BA, N05CA, N05CB, N05CD, and N05CF. Benzodiaze-
pines and barbiturates counted as antiepileptic drugs if they
were given for epilepsy (in which case they had the ATC
code N03AA or N03AE), and as sedatives if they were given
for anxiety or as sedation. Age, MELD score, biochemistry,
and diuretics were included as continuous, linear variables,
and all confounders were included as time-dependent
variables. In addition, we repeated the Cox regression ana-
lysis within the stratum of patients with cirrhosis due to
alcoholism.
Sensitivity analysis
The clinical diagnosis of the low grades of HE may be
uncertain so we repeated our analyses with overt HE as
the outcome, i.e. HE grades 2, 3, or 4 [8]. We also re-
peated our analyses excluding patients who had experi-
enced one or more HE episodes before randomization.
This exclusion reduced the possibility that we included
patients who had minimal HE, but it also reduced the
number of patients in the study.
Results
We included 1120 cirrhosis patients, 21 (1.9 %) of whom
had a recorded diagnosis of epilepsy. During the total
follow-up time of 622.2 person-years, 304 cirrhosis pa-
tients had an HE episode, and 45 died without having
developed HE. The 21 cirrhosis patients who had epi-
lepsy had less severe cirrhosis, as judged by their MELD
scores (Table 1), and only one of them died during the
trials. This patient died after his first HE episode, i.e.
after follow-up ended in our current analysis of the trial
data. Despite their favorable MELD scores, seven of the
21 cirrhosis patients with epilepsy had an HE episode
during the follow-up. The HE incidence rate was 0.67
episodes per person-year for the 21 cirrhosis patients
with epilepsy (seven episodes during 10.5 person-years,
Table 1 Characteristics of the study cohort at the beginning of follow-up
Epilepsy Not epilepsy p-value
Number of patients 21 1099
Men (%) 18 (86 %) 760 (69 %) 0.10
Age (median, IQR) 54 (45–59) 57 (50–64) 0.04
Cirrhosis etiology 0.22
Alcohol alone (%) 16 (76 %) 634 (58 %)
Hepatitis C alone (%) 1 (5 %) 147 (13 %)
Other (%) 4 (19 %) 318 (29 %)
Diabetes (%) 4 (19 %) 256 (23 %) 0.65
History of HE before randomization (%) 4 (19 %) 251 (23 %) 0.68
MELD score (median, IQR) 7.9 (4.6–11.3) 11.4 (8.1–14.4) 0.02
Sodium, mmol/L (median, IQR) 136 (133–138) 137 (134–139) 0.34
Albumin, g/L (median, IQR) 33 (29–37) 33 (29–37) 0.68
Lactulose, any dose (%) 14 (19 %) 330 (30 %) 0.28
Rifaximin, any dose (%) 0 (0 %) 27 (2 %) 0.45
Benzodiazepine/barbiturates, any dose (%) 2 (10 %) 95 (9 %) 0.89
IQR interquartile range, 25th percentile to 75th percentile
Jepsen et al. BMC Gastroenterology  (2016) 16:77 Page 3 of 6
median 0.42 years of follow-up per patient) compared
with 0.49 episodes per person-year for the 1099 cirrhosis
patients without epilepsy (297 episodes during 611.7
person-years, median 0.58 years of follow-up per patient).
After confounder adjustment, the rate of HE for patients
with epilepsy vs. controls was more than doubled (ad-
justed HR = 2.12, 95 % CI 0.99–4.55), but the association
was not statistically significant (Table 2). Among the 650
patients with alcoholic cirrhosis, the corresponding
confounder-adjusted HR was 2.44 (95 % CI 0.96–6.17).
When we re-categorized patients, eight patients
(0.7 %) had definite epilepsy; 12 (1.1 %) had a history of
seizures but did not currently use antiepileptic drugs; 16
(1.4 %) used antiepileptic drugs for non-epilepsy indica-
tions, primarily neuropathic pain; and the remaining
1084 (96.8 %) were controls. Thus, one patient with a re-
corded diagnosis of epilepsy was re-categorized as a con-
trol after neurologists reviewed the available data. The
eight patients with definite epilepsy used very different
drug regimens: two used topiramate, one used pheny-
toin + gabapentin (and developed HE), one used pheny-
toin + valproate, one used gabapentin (and developed
HE), one used carbamazepine, one used oxcarbazepine
(and developed HE), and one used phenobarbital. In this
analysis with four patient categories the hazard ratio es-
timates had wider confidence intervals because the pa-
tient groups were smaller, but the point estimate for
‘definite epilepsy’ vs. controls (adjusted HR = 2.49, 95 %
CI 0.78–7.90) was essentially the same as the estimate
for ‘epilepsy’ vs. controls in the primary analysis
(Table 3). Also the patients we classified as having un-
specified seizures and those who used antiepileptic drugs
for non-epilepsy indications had higher HE rates than
the controls, but their HE rates were not as high as the
HE rate among patients with definite epilepsy (Table 3).
Sensitivity analysis
There were 151 overt HE episodes during the follow-up,
including six among the 21 cirrhosis patients with a re-
corded diagnosis of epilepsy. These 21 patients’ adjusted
hazard ratio of overt HE vs. controls was 3.83 (95 % CI
1.65–8.87). When we re-categorized patients, the ad-
justed hazard ratio for patients with definite epilepsy vs.
controls was 3.60 (95 % CI 0.86–15.06). It was 2.99
(95 % CI 0.92–9.75) for patients with unspecified sei-
zures vs. controls, and 1.20 (95 % CI 0.38–3.86) for pa-
tients who used antiepileptic drugs for non-epilepsy
indications vs. controls.
Finally, when we excluded the 255 patients with an HE
episode before randomization the association between
epilepsy and HE strengthened. The adjusted hazard ratio
was 4.78 (95 % CI 1.92–11.88) for epilepsy patients vs.
controls. After re-categorization it was 6.12 (95 % CI
1.47–25.44) for patients with definite epilepsy vs.
controls, 2.97 (95 % CI 0.71–12.44) for patients with
unspecified seizures vs. controls, and 2.76 (95 % CI
Table 2 Confounder-adjusted effect of a recorded diagnosis of
epilepsy on the hazard rate of HE episodes grade 1, 2, 3, or 4
Adjusted hazard ratio
Epilepsy (as recorded) 2.12 (0.99–4.55)
Male vs. female 1.07 (0.83–1.39)
Age, per 10-year increase 1.17 (1.04–1.32)
Cirrhosis etiology
Alcohol alone (%) 1 (reference)
Hepatitis C alone (%) 1.64 (1.18–2.28)
Other (%) 1.35 (1.03–1.76)
Diabetes 1.41 (1.09–1.82)
History of HE before randomization 1.72 (1.34–2.20)
MELD score, per point 1.09 (1.07–1.11)
Sodium, per 5 mmol/L increase 0.64 (0.58–0.71)
Albumin, per 5 g/L increase 0.78 (0.70–0.87)
Lactulose, any dose vs. none 1.79 (1.41–2.28)
Rifaximin, any dose vs. none 0.59 (0.32–1.10)
Benzodiazepines/barbiturates, any dose vs. none 1.22 (0.85–1.74)
Table 3 Confounder-adjusted effects of definite epilepsy,
unspecified seizures, and use of antiepileptic drugs for non-epilepsy
indications on the hazard rate of HE episodes grade 1, 2, 3, or 4
Adjusted hazard
ratio
Patient category (after re-categorization)
Definite epilepsy 2.49 (0.78–7.90)
Unspecified seizures 1.50 (0.47–4.76)




Male vs. female 1.08 (0.83–1.40)
Age, per 10-year increase 1.17 (1.03–1.32)
Cirrhosis etiology
Alcohol alone (%) 1 (reference)
Hepatitis C alone (%) 1.65 (1.19–2.30)
Other (%) 1.35 (1.03–1.76)
Diabetes 1.38 (1.06–1.78)
History of HE before randomization 1.70 (1.33–2.18)
MELD score, per point 1.09 (1.07–1.11)
Sodium, per 5 mmol/L increase 0.63 (0.57–0.70)
Albumin, per 5 g/L increase 0.78 (0.70–0.87)
Lactulose, any dose vs. none 1.80 (1.41–2.29)
Rifaximin, any dose vs. none 0.59 (0.32–1.11)
Benzodiazepines/barbiturates, any dose vs. none 1.23 (0.86–1.76)
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1.11–6.86) for patients who used antiepileptic drugs for
non-epilepsy indications vs. controls.
Discussion
This study was based on an unparalleled dataset with de-
tailed clinical data on more than 1100 cirrhosis patients.
We examined the association between epilepsy and HE
and found similar hazard ratio estimates whether we de-
fined epilepsy per the recorded diagnoses, or we used all
available information to identify patients with definite epi-
lepsy. Moreover, the association strengthened when we
considered only episodes of overt HE, or when we ex-
cluded patients with HE episodes before inclusion. There-
fore, this study provides evidence that epilepsy is a risk
factor for developing HE, despite the small number of pa-
tients with epilepsy.
Our motivation for this study was to understand why
epilepsy was associated with a 1.31-fold increased mor-
tality among patients with cirrhosis [1]. We could not
confirm that association in these trial data because the
21 patients with epilepsy had so well-preserved liver
function that only one of them died during the 1-year
follow-up in the trials. Nevertheless, epilepsy’s associ-
ation with HE development in the trial data suggests
that epilepsy might also have been a risk factor for mor-
tality if patients had been followed for longer than 1 year.
It is evident that this study is limited by the small num-
ber of patients with epilepsy and the short duration of
follow-up, but a stronger dataset will not emerge in the
foreseeable future.
The cirrhosis-related data for these analyses were
rigorously defined, but the data regarding epilepsy were
not. Epilepsy diagnoses were recorded by the hepatolo-
gists caring for the patients, and we had no information
that explained why patients with epilepsy were not re-
ceiving antiepileptic treatment—were they uncompliant
with recommended antiepileptic treatment, or did they
in fact not have epilepsy? That uncertainty led us to re-
categorize patients and define a patient group with def-
inite epilepsy. It is a crucial finding that the hazard ratio
estimates were similar for the larger ‘epilepsy’ and the
smaller ‘definite epilepsy’ group (2.12 and 2.49, respect-
ively). It is obvious that the confidence interval was
wider for the smaller group, but the fact that the esti-
mates were similar supports the conclusion that epilepsy
is indeed a risk factor for developing HE.
It is likely that some of those with a recorded diagno-
sis of epilepsy who did not receive antiepileptic treat-
ment (those we categorized as having ‘unspecified
seizures’) did in fact have epilepsy. That possibility might
explain why this group of patients had an increased HE
risk. The effect of antiepileptic drugs for non-epilepsy
indications was ambiguous, and we are concerned that
the HE episodes might be related to the indication for
the antiepileptic drug rather than to the drug itself. For
example, some of the cirrhosis patients without epilepsy
who used antiepileptic drugs suffered from diabetes or
alcoholism, both of which are risk factors for neur-
opathy, the prevailing indication for some antiepileptic
drugs. Diabetes itself is a risk factor for HE [9], and alco-
holism can cause symptoms and signs that might be
mistaken for HE [7]. Although we controlled for both
conditions in our analysis, these patients could have
worse diabetes or worse alcoholism than other patients,
in which case residual confounding would cause us to
overestimate the effect of antiepileptic drugs. That con-
cern, coupled with the imprecise hazard ratio esti-
mate, means that we do not claim that antiepileptic
drugs cause HE, although the sedative properties of
some antiepileptic drugs could potentially increase the
risk of HE.
It is conceivable that some events perceived as HE epi-
sodes were in fact non-convulsive status epilepticus,
which may resemble grade 4 HE [2, 3]. However, only
one patient with epilepsy had a grade 4 HE episode, and
that episode had an identified precipitant (electrolyte
disturbance) and occurred in a patient who had previ-
ously had HE. We are not concerned by the risk of mis-
taking grade 1 HE episodes for post-ictal disorientation
because our sensitivity analysis showed that epilepsy was
an even stronger risk factor for overt HE, which is con-
sidered a more reliable clinical diagnosis [8].
Our data on the association between epilepsy and HE
are merely observational and do not clarify any patho-
genetic aspect of HE beyond the obvious disturbed func-
tion of the central nervous system [10]. It remains very
intriguing that a condition with overshoot of excitatory
neurotransmission increases the risk of developing a
condition characterized by neuroinhibition [11, 12]. Our
findings are probably best viewed in light of the concept
of the ‘frail brain’ [13], whereby the cirrhosis patient’s
brain responds with HE to anything that affects
neurotransmission, but the links between epilepsy, anti-
epileptic drugs, and HE risk clearly deserve further
investigation.
Conclusions
In these data from three worldwide randomized trials in
cirrhosis patients with ascites, epilepsy seemed to cause
an increased risk of HE. This finding may help us under-
stand the pathogenesis of HE and improve our clinical
management of patients with cirrhosis and epilepsy.
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